Patients with SE-AN can make meaningful improvements with both therapies. Both treatments were acceptable and high retention rates at follow-up were achieved. Between-group differences at follow-up were consistent with the nature of the treatments given.
Background. The psychological morbidity, functional impairment, and disturbance in psychosocial adjustment to illness was evaluated in relation to breast cancer‐related arm swelling.
Methods. Fifty women with breast cancer‐related arm swelling were matched with 50 control subjects for age, duration since treatment, and type of treatment received. All study participants were free from active disease and had been treated more than 1 year ago.
Results. Patients with arm swelling showed greater psychological morbidity at formal psychiatric interview, impaired adjustment to illness as evaluated by the Psychosocial Adjustment to Illness Scale, and greater impairment of physical functioning.
Conclusions. Patients with arm swelling in relation to breast cancer experienced functional impairment, psychosocial maladjustment, and increased psychological morbidity. These findings have implications for management of breast cancer.
Mirror confrontation is a more effective form of exposure because of the strong emotional response it elicits. Patients' pronounced emotional response to this exercise allowed easier identification of the affective and behavioral components of body dissatisfaction and more cogent links into a developmental body image timeline.
Findings suggest that improvements in QoL may be dependent on symptom change and weight gain. Treatments seeking solely to improve QoL may be unlikely to produce lasting change and clinicians should maintain a focus on weight and behavioral symptoms as much as on improvements in QoL.
Results demonstrated overall good replicability of the SCOFF administered as a written questionnaire compared to oral interview. Two trends were noted. The first was towards higher scores with written versus oral delivery irrespective of order, possibly indicating enhanced disclosure via written format. The second was of less consistency where verbal preceded written responses. Altogether findings support use of the SCOFF where a concise, valid and reliable screening for eating disorders is required in written form.
This study tested a new schema-based cognitive-behavioural model of eating disorders. The model is predicated on the assumption that important differences between bulimic and restrictive psychopathology exist at the level of schema processing. To test this model, 134 females with eating disorders and 345 non-eating disordered females were recruited. Factor analyses validated the measures used. Three factors emerged for primary avoidance of affect (strategies to avoid the activation of emotion), and two for secondary avoidance of affect (strategies to reduce the experience of emotion once it has been triggered). As predicted, primary and secondary avoidance of affect were found in anorexia, where anorexics of the binge/purge subtype displayed the highest levels. In contrast, secondary avoidance of affect was found to characterise bulimia nervosa, and this avoidance was confined to the behavioural/somatic domain. These findings cannot be explained by existing models of eating disorders, but offer some support for the proposed schema-based model. Treatment implications are discussed, and it is suggested that cognitive-behavioural treatments might be extended to address schema processes in order to help those who suffer from eating-disorders to change their behaviours.Despite differences in the physical and behavioural characteristics of anorexia nervosa and bulimia nervosa, studies show similarities in cognitive and emotional profiles across the disorders (e.g.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.